Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

8b5ca3cf-7fa2-420a-896c-be6b528e3f55 - samples

ABSTRACT: The data includes exome seuqencing FASTQ files of 192 patients receiving immune checkpoint blockade therapy. The data only provides for WXS of tumor tissue.

PROVIDER: EGAD00001009101 | EGA |

REPOSITORIES: EGA

ACCESS DATA

Json Xml

Similar Datasets

scRNA-seq analysis demonstrate alterations in TICs of the TME during TREM1 inhibition and anti-PD-1 treatment in B16F10 melanoma

Project description:To comprehensively characterize the changes within the TME during TREM1 deficiency and anti-PD-1 immune checkpoint blockade therapy, we performed scRNA-seq analysis of the CD45+ TICs in melanoma-bearing C57BL/6 mice receiving the various treatments. We analyzed approximately 8,249 CD45+ cells from the treatment groups with t-SNE analysis, identifying 10 distinct clusters of tumor-infiltrating immune cells

2023-09-27 | E-MTAB-13300 | biostudies-arrayexpress

Mutations in CHEK2 affect the tumor immune microenvironment and increase the response to PD-1 inhibitor therapy

Project description:To elucidate whether CHEK2 mutations has effects on tumor microenvironment after immune checkpoint blockade therapy, we performed RNA-seq analysis of tumor tissues of mice receiving PBS or anti-PD-1 therapy to compare the gene expression profiles.

2023-11-13 | GSE233981 | GEO

Mutations in CHEK2 affect the tumor immune microenvironment and increase the response to PD-1 inhibitor therapy

Project description:To elucidate whether CHEK2 mutations has a similar effect on the tumor microenvironment and response to immune checkpoint blockade therapy as mutations in POLE, we performed RNA-seq analysis of tumor tissues of mice receiving PBS or anti-PD-1 therapy to compare the gene expression profiles.

2023-11-13 | GSE233162 | GEO

MHC II immunogenicity shapes the neoepitope landscape in human tumors

Project description:DeepNeo predicts immunogenic neoantigens for both MHC I and II responsive to immune checkpoint blockade therapy. Furthermore, spontaneous immunity was observed in pancancer manner for MHC II.

2022-11-14 | PRJEB57400 | EVA

Mus musculus

Project description:Dietary Lactobacillus-derived exopolysaccharide enhances immune checkpoint blockade therapy

| PRJDB12989 | ENA

Evaluation of targeted and immune combination therapies in a rat model of hormone receptor-positive breast cancer [scRNA]

Project description:Breast cancer hormone receptor (HR) estrogen and progesterone (ER/PR) positive tumors were generated in an outbred rat model (Sprague-Dawley) through the injection of the carcinogen N-nitrosomethylurea (NMU). These tumors were treated with immune checkpoint blockade (anti PD-L1) in combination with targeted therapies, including an TBK1/IKBKE inhibitor, a KMT5B/C inhibitor, a TGF-b inhibitor, and a selective estrogen receptor degrader (SERD). This dataset includes single-cell RNA sequencing (scRNA-seq) data from tumors subjected to various treatment setups. Whole-tumor digestion was performed to preserve a comprehensive representation of the tumor microenvironment. The study aims to identify mechanisms that sensitize HR postive tumor subtypes to immune checkpoint blockade therapy.

2026-01-11 | GSE284698 | GEO

Evaluation of targeted and immune combination therapies in a rat model of hormone receptor-positive breast cancer [RNA]

Project description:Breast cancer hormone receptor (HR) estrogen and progesterone (ER/PR) positive tumors were generated in an outbred rat model (Sprague-Dawley) through the injection of the carcinogen N-nitrosomethylurea (NMU). These tumors were treated with immune checkpoint blockade (anti PD-L1) in combination with targeted therapies, including an TNK1/IKBKE inhibitor, a KMT5B/C inhibitor, a TGF-b inhibitor, and a selective estrogen receptor degrader (SERD). This dataset includes single-cell RNA sequencing (scRNA-seq) data from tumors subjected to various treatment setups. Whole-tumor digestion was performed to preserve a comprehensive representation of the tumor microenvironment. The study aims to identify mechanisms that sensitize HR postive tumor subtypes to immune checkpoint blockade therapy.

2026-01-12 | GSE304911 | GEO

Radiation Therapy Inhances Immunotherapy Response in Microsatellite-stable Colorectal and Pancreatic Adenocarcinoma in a Phase II Trial

Project description:Immune checkpoint blockade has limited efficacy in microsatellite stable (MSS) colorectal (CRC) and pancreatic (PDAC) cancer. Preclinical models have demonstrated the use of radiation to activate the innate immune response and stimulate responsiveness to immune checkpoint blockade. Here, we describe a Phase 2 trial of radiation therapy combined with combined anti-CTLA4 (ipilimumab) and anti-PD1 (nivolumab) antibodies in MSS CRC and PDAC. In the per protocol analysis disease control rate was 37% (10/27) in CRC and 29% (5/17) in PDAC with an overall response rate of 15% (4/27) and 18% (3/17), respectively. Whole exome and RNA sequencing of biopsies from 17 patients revealed low tumor mutational burden in all tumors, but a notable upregulation of interferon stimulated genes with concordant high expression of multiple repeat RNA transcripts in responders. Altogether, this study provides foundational human proof of concept of radiation with combination immune checkpoint blockade therapy in otherwise immunotherapy resistant cancers.

2021-07-06 | GSE179351 | GEO

DRUP-MSI metagenomic data

Project description:Microbial metabolic pathways guide response to immune checkpoint blockade therapy

| PRJEB91542 | ENA

Combinatorial therapy to target melanoma resistant to immune checkpoint blockade

Project description:Combinatorial therapy to target melanoma resistant to immune checkpoint blockade

| PRJNA1102317 | ENA